Edition:
United Kingdom

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

18.90USD
19 Jan 2018
Change (% chg)

$-0.88 (-4.45%)
Prev Close
$19.78
Open
$19.83
Day's High
$19.97
Day's Low
$18.79
Volume
13,649
Avg. Vol
--
52-wk High
$25.33
52-wk Low
$12.51

Chart for

About

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment

* APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2

20 Dec 2017

BRIEF-Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO

* APELLIS PHARMACEUTICALS EXPANDS MANAGEMENT TEAM, APPOINTS TIMOTHY SULLIVAN CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

19 Dec 2017

BRIEF-Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc

* Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing Source text (http://bit.ly/2jcJaxu) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

21 Nov 2017

Earnings vs. Estimates